BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Mar 14, 2025 • 11min
From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing
Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle cell disease that is now called CASGEVY. He describes what it was like receiving the treatment, and discusses the need for more awareness and access in the sickle cell community worldwide for this type of treatment.
Mar 14, 2025 • 19min
Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target
Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good Therapeutics, and how the follow-on company Bonum aims to test this approach more broadly. He describes how it works, and discusses the initial programs they have chosen, with a LAG3-IL2 being the most advanced.
Mar 14, 2025 • 6min
Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in Seattle
He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on portfolio companies eGenesis and Vir Biotechnology.
Mar 14, 2025 • 6min
Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!
Celebrating with the Seattle (and beyond) biotech community.
Mar 13, 2025 • 7min
Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome
CEO Jame Mcllroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to read out immanently.
Mar 13, 2025 • 6min
Tour of Scotland: Scotland's Chief Scientist (Health) describes how new technologies are being embraced in the NHS, and why Scotland is a good place for global companies to run clinical trials
Professor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital dermatology, and invites companies to run clinical trials in Scotland.
Mar 13, 2025 • 17min
HumanX: Generate Biomedicines' CEO Mike Nally describes how he sees AI going from improvements in optimization to drugging the undruggable
From the big HumanX AI conference in Las Vegas, he describes the overall path he sees AI taking in its contributions to drug development, and gives an update on Generate's programs regarding TSLP, IL13, ADCs, and more.
Mar 13, 2025 • 6min
Tour of Scotland: St. Andrews based Pneumagen aims to prevent viral respiratory infections with an intra-nasally delivered platform that harnesses glycan targeted Carbohydrate Binding Module domains
Co-Founder & CEO Douglas Thomson describes how the company was founded, and walks us through the science. Plus, a recap of recently presented phase 2 data, and the road ahead.
Mar 13, 2025 • 6min
Tour of Scotland: Dundee based Glen Clova Scientific is using virus like particles to lower levels of cytokines in patients experiencing chronic inflammatory conditions
CEO Steven Powell joins BiotechTV from Scotland's Life Sciences Conference and Awards in Glasgow, and explains Glen Clova's expertise in making next generation VLPs. The first clinical program will be in senile pruritus, targeting IL-31.
Mar 13, 2025 • 7min
Tour of Scotland: Mark Cook, Co-Chair of Life Sciences Scotland describes the importance of life sciences to the area and what the government and industry are doing to support it
He describes the assets that Scotland has to offer the industry such as excellent universities that derive innovation and a diverse population that makes it a great region for clinical trials.
